Want to see HK:9969 full AI Analyst Report?
Top Page
InnoCare Pharma Ltd.
(9969)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$16.00
▲(36.17% Upside)
Action:Reiterated
Date:08/27/26
The score is driven primarily by improved financial performance (notably the profitability turnaround and strong margins) and a constructive technical trend. The latest earnings call adds support via reiterated >35% drug sales growth guidance, return to profitability, and strong liquidity, while the main constraints are weaker cash conversion consistency and a valuation that offers limited cushion without a dividend.
Positive Factors
Revenue and Profitability Turnaround
The sharp increase in revenue and return to profitability show stronger commercial execution and operating leverage. If drug sales continue expanding, this earnings inflection can provide greater funding for R&D and reduce dependence on external capital.
Negative Factors
Revenue Concentration
Dependence on one leading product makes near-term revenue vulnerable to competition, reimbursement decisions, safety findings or slower growth. Diversification will take time because newer products currently contribute relatively little to the commercial base.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profitability Turnaround
The sharp increase in revenue and return to profitability show stronger commercial execution and operating leverage. If drug sales continue expanding, this earnings inflection can provide greater funding for R&D and reduce dependence on external capital.
Read all positive factors
InnoCare Pharma Ltd. (9969) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$22.97B
Dividend YieldN/A
Average Volume (3M)7.83M
Price to Earnings (P/E)25.3
Beta (1Y)0.90
Revenue Growth117.39%
EPS GrowthN/A
CountryHK
Employees1,388
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.52
Shares Outstanding1,496,284,200
10 Day Avg. Volume8,587,886
30 Day Avg. Volume7,830,575
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.82Price Target Upside68.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.19
Revenue Forecast (FY)HK$2.51B
InnoCare Pharma Ltd. Business Overview & Revenue Model
Company Description
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a...
How the Company Makes Money
InnoCare Pharma generates revenue primarily by commercializing approved medicines and selling them through pharmaceutical distribution channels to hospitals, clinics, and pharmacies, where applicable. A second major source of income is collaborati...
InnoCare Pharma Ltd. Earnings Call Summary
Earnings Call Date:Aug 24, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call presents a strongly positive commercial and financial picture in H1 2026: double-digit topline growth (55.5% YoY), a return to profitability (RMB 240 million net profit), strong cash (~RMB 8.4 billion) and positive operating cash flow. R&D investment is ongoing with multiple regulatory approvals/submissions, several Phase III successes, and broad pipeline progress (notably mesutoclax and ADC programs). Key risks are timing and execution of large Phase III programs, dependence on orelabrutinib for near-term revenue, the early-stage nature of many solid tumor programs, BD deal timing uncertainty, and safety/enrollment risks in some autoimmune programs. Overall, the highlights (robust growth, profitability, cash, approvals, and positive late‑stage data) outweigh the lowlights (timing, execution and competitive risks).Positive Updates
Strong Revenue Growth
Total revenue of RMB 1.137 billion in H1 2026, up 55.5% year-over-year.
Negative Updates
Revenue Concentration in Orelabrutinib
Management noted orelabrutinib contributed the majority of value growth (>30% growth for orelabrutinib) while tafasitamab and zurletrectinib, though showing high growth rates off a low base, remain small absolute contributors and zurletrectinib is not yet on NRDL.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Total revenue of RMB 1.137 billion in H1 2026, up 55.5% year-over-year.
Read all positive updates
Company Guidance
Management reiterated confidence in 2026 financial and operational targets: full‑year drug sales growth above 35% (building on H1 drug sales of RMB 918m, +43.2% YoY) and strong topline momentum after H1 total revenue of RMB 1.137bn (+55.5% YoY); H1 net profit was RMB 240m (vs a RMB 36m loss a year ago) with diluted EPS of RMB 0.14 and management expects full‑year profitability with EPS above the H1 level. Liquidity and investment metrics were highlighted—cash and related accounts of ~RMB 8.4bn (~$1.2bn) as of June 30, positive operating cash flow in H1, and R&D spend of RMB 497m (up 10.5% YoY)—and the company guided to multiple near‑term clinical and regulatory catalysts (e.g., first‑line CLL/SLL Phase III fixed‑duration readout H1 2027, anticipated ITP NDA approval by H1 2027, Phase I completions for ICP‑538 and ICP‑054 by year‑end, and a US IND for ICP‑B381 expected in September) to drive continued commercial expansion.InnoCare Pharma Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
73
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.75B | 2.30B | 1.01B | 738.54M | 625.40M | 1.04B |
| Gross Profit | 2.48B | 2.01B | 871.01M | 610.10M | 482.01M | 977.37M |
| EBITDA | 862.74M | 555.89M | -463.49M | -516.55M | -808.28M | 16.23M |
| Net Income | 907.26M | 625.84M | -440.63M | -631.26M | -886.59M | -64.55M |
Balance Sheet | ||||||
| Total Assets | 11.22B | 10.83B | 9.41B | 9.92B | 10.32B | 7.40B |
| Cash, Cash Equivalents and Short-Term Investments | 8.37B | 7.34B | 6.22B | 8.22B | 9.01B | 6.25B |
| Total Debt | 2.23B | 1.61B | 1.27B | 1.35B | 1.25B | 1.27B |
| Total Liabilities | 3.22B | 2.79B | 2.66B | 2.74B | 2.68B | 1.74B |
| Stockholders Equity | 7.67B | 7.73B | 6.73B | 7.15B | 7.60B | 5.60B |
Cash Flow | ||||||
| Free Cash Flow | 236.02M | 130.80M | -443.78M | -926.00M | -935.88M | -11.00K |
| Operating Cash Flow | 320.62M | 199.15M | -365.55M | -671.34M | -565.55M | 167.06M |
| Investing Cash Flow | -694.17M | -358.03M | 1.11B | 666.91M | -1.73B | -1.73B |
| Financing Cash Flow | 566.66M | -32.84M | -285.60M | 1.31M | 3.09B | 2.54B |
InnoCare Pharma Ltd. Technical Analysis
Positive
11.75
Price Trends
14.04
Positive
13.26
Positive
13.15
Positive
Market Momentum
0.22
Negative
60.38
Neutral
65.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9969, the sentiment is Positive. The current price of 11.75 is below the 20-day moving average (MA) of 14.65, below the 50-day MA of 14.04, and below the 200-day MA of 13.15, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 60.38 is Neutral, neither overbought nor oversold. The STOCH value of 65.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9969.
InnoCare Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$22.97B | 25.34 | 12.35% | ― | 117.39% | ― | |
66 Neutral | HK$26.93B | 61.04 | 15.79% | ― | 48.04% | 166.72% | |
52 Neutral | HK$23.57B | -15.19 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$9.74B | -19.63 | -43.54% | ― | 116.67% | -0.42% | |
45 Neutral | HK$12.97B | -7.70 | -153.78% | ― | 70.26% | -12.79% | |
44 Neutral | HK$7.98B | -71.65 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:9969
InnoCare Pharma Ltd.
14.80
-3.13
-17.46%
HK:9688
Zai Lab Ltd
20.08
-5.24
-20.70%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.26
-9.80
-42.50%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
58.00
32.16
124.46%
HK:2616
CStone Pharmaceuticals
6.07
-6.83
-52.95%
HK:6855
Ascentage Pharma Group International
33.58
-47.67
-58.67%
InnoCare Pharma Ltd. Corporate Events
InnoCare Pharma Swings to Profit on Surging Drug Sales and New Launches
Aug 24, 2026
InnoCare Pharma reported a sharp increase in interim revenue, with total income rising 55.5% to RMB1,137.1 million in the six months ended 30 June 2026, driven by 43.2% growth in drug sales to RMB918.1 million. The performance was supported by sus...
InnoCare Pharma Sets Board Meeting to Approve 2026 Interim Results
Aug 11, 2026
InnoCare Pharma Limited has scheduled a board meeting for 24 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also approve the publication of these results, a routine but important step th...
InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory Filing
Jul 27, 2026
InnoCare Pharma announced that its Phase III registrational trial of fadeucravacitinib (ICP‑488) in adults with moderate‑to‑severe plaque psoriasis met its primary endpoint with statistically significant and clinically meaningful...
InnoCare’s TYK2 Inhibitor Soficitinib Delivers Positive Phase II Results in Non-Segmental Vitiligo
Jul 16, 2026
InnoCare Pharma reported positive topline data from the Phase II portion of its ongoing Phase II/III adaptive trial of soficitinib (ICP-332), an internally discovered next-generation oral TYK2 inhibitor, in adult patients with non-segmental vitili...
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis
Jul 15, 2026
InnoCare Pharma announced that its Phase III registrational trial of soficitinib, an internally developed next-generation oral TYK2 inhibitor, in adults with moderate-to-severe atopic dermatitis met its primary endpoint with statistically signific...
InnoCare Pharma Grants Performance-Linked RSUs Under 2023 Share Award Scheme
Jun 30, 2026
InnoCare Pharma Limited has granted 1,910,000 restricted share units under its 2023 Share Award Scheme to eight employees, including a member of senior management, equivalent to about 0.11% of its issued share capital. The RSUs carry a purchase pr...
InnoCare Shareholders Approve All Resolutions at 2026 AGM
Jun 16, 2026
InnoCare Pharma Limited reported that all resolutions tabled at its annual general meeting on 16 June 2026 were approved by shareholders via poll, covering financial statements, the 2025 annual and board work reports, and the profit distribution p...
InnoCare Pharma Launches 2026 RMB Share Incentive Scheme with First Grant of Restricted Shares
Jun 16, 2026
InnoCare Pharma has implemented its 2026 RMB Share Incentive Scheme, following shareholder approval at its annual general meeting, and granted 8,000,000 restricted shares to 100 participants. The grant represents about 0.45% of the company’s...
InnoCare Pharma Names New Joint Company Secretary and Secures Listing Rules Waiver
Jun 5, 2026
InnoCare Pharma has appointed senior director of investor relations Yuan Bei as a joint company secretary effective 5 June 2026, alongside existing secretary Lin Sio Ngo. Yuan brings over a decade at the company, board office management experience...
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
May 28, 2026
InnoCare Pharma said China’s Center for Drug Evaluation has accepted its new drug application for orelabrutinib, a Bruton Tyrosine Kinase inhibitor, for treating primary immune thrombocytopenia in China. The move expands orelabrutinib’...
InnoCare Wins Australian Approval for Lymphoma Drug Orelabrutinib
May 27, 2026
InnoCare Pharma has secured approval from Australia’s Therapeutic Goods Administration for its BTK inhibitor orelabrutinib, branded as HIBRUKA, to treat adult patients with relapsed or refractory mantle cell lymphoma, an aggressive B-cell no...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.